Saturday, October 29, 2016 9:21:44 AM
oh my gosh..the pain the agony..it's hard to take..honestly..
i read this meandering worry after worry after worry and you would think
the good Dr. has betrayed us at every turn! made horrible hiring decisions, failed every test..sold his own shares into rallies, put his girlfriend and wife on payroll(different departments-of course) and given his mother options(AXON Style)...
ALL ONLY because they won't give up Outstanding Share count?
We know we have TWO Phase 2/3 Clinicals coming in 2017!
Confirmed by Rett Syndrome Assoc. and Caulfield Hospital..
and really we have 3(Parkinsons) if you read the last PR from Anavex regarding Ariana properly.
We have how many IND's and how many FDA Designations and are working with BIOGEN, MJFF, really on and on and on..
and the palpable trepidation..that they won't give out share count?
Look the good Dr. has said he doesn't need anymore money..right?
so an In-Licensing Deal could include..a number of shares in Anavex to the right Partner..Anavex would do this to incentive the partner for $$$ and a more lucrative deal for Anavex shareholders..as our Partner is now entwined with OUR interests..
Honestly it is so disappointing to read this Board of all the longs and all the good Dr. has acoomplished with so little capital and just see the fear..Reminds me of a story about people falling asleep, when their great friend had gone to meditate and asked to stay awake.
With Longs like this, it it no wonder the Motley Fools, The Fuesrteinns and the Market Makers find fertile ground to short tops..
WOW
i read this meandering worry after worry after worry and you would think
the good Dr. has betrayed us at every turn! made horrible hiring decisions, failed every test..sold his own shares into rallies, put his girlfriend and wife on payroll(different departments-of course) and given his mother options(AXON Style)...
ALL ONLY because they won't give up Outstanding Share count?
We know we have TWO Phase 2/3 Clinicals coming in 2017!
Confirmed by Rett Syndrome Assoc. and Caulfield Hospital..
and really we have 3(Parkinsons) if you read the last PR from Anavex regarding Ariana properly.
We have how many IND's and how many FDA Designations and are working with BIOGEN, MJFF, really on and on and on..
and the palpable trepidation..that they won't give out share count?
Look the good Dr. has said he doesn't need anymore money..right?
so an In-Licensing Deal could include..a number of shares in Anavex to the right Partner..Anavex would do this to incentive the partner for $$$ and a more lucrative deal for Anavex shareholders..as our Partner is now entwined with OUR interests..
Honestly it is so disappointing to read this Board of all the longs and all the good Dr. has acoomplished with so little capital and just see the fear..Reminds me of a story about people falling asleep, when their great friend had gone to meditate and asked to stay awake.
With Longs like this, it it no wonder the Motley Fools, The Fuesrteinns and the Market Makers find fertile ground to short tops..
WOW
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
